26 results on '"Zheng, Qiufan"'
Search Results
2. Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study.
- Author
-
Jiang, Kuikui, Hong, Ruoxi, Xia, Wen, Lu, Qianyi, Li, Liang, Huang, Jianhao, Shi, Yanxia, Yuan, Zhongyu, Zheng, Qiufan, An, Xin, Xue, Cong, Huang, Jiajia, Bi, Xiwen, Chen, Meiting, Zhang, Jingmin, Xu, Fei, and Wang, Shusen
- Subjects
HER2 positive breast cancer ,METASTATIC breast cancer ,EPIDERMAL growth factor receptors ,VINORELBINE ,LEUKOCYTE count - Abstract
Purpose This study aims to evaluate the efficacy and safety of a new combination treatment of vinorelbine and pyrotinib in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) and provide higher level evidence for clinical practice. Materials and Methods This was a prospective, single-arm, phase 2 trial conducted at three institutions in China. Patients with HER2-positive MBC, who had previously been treated with trastuzumab plus a taxane or trastuzumab plus pertuzumab combined with a chemotherapeutic agent, were enrolled between March 2020 and December 2021. All patients received pyrotinib 400 mg orally once daily plus vinorelbine 25 mg/m2 intravenously or 60-80 mg/m2 orally on day 1 and day 8 of 21-day cycle. The primary endpoint was progression-free survival (PFS), and the secondary endpoints included the objective response rate (ORR), disease control rate (DCR), overall survival, and safety. Results A total of 39 patients were enrolled. All patients had been pretreated with trastuzumab and 23.1% (n=9) of them had accepted trastuzumab plus pertuzumab. The median follow-up time was 16.3 months (95% confidence interval [CI], 5.3 to 27.2), and the median PFS was 6.4 months (95% CI, 4.0 to 8.8). The ORR was 43.6% (95% CI, 27.8% to 60.4%) and the DCR was 84.6% (95% CI, 69.5% to 94.1%). The median PFS of patients with versus without prior pertuzumab treatment was 4.6 and 8.3 months (p=0.017). The most common grade 3/4 adverse events were diarrhea (28.2%), neutrophil count decreased (15.4%), white blood cell count decreased (7.7%), vomiting (5.1%), and anemia (2.6%). Conclusion Pyrotinib plus vinorelbine showed promising efficacy and tolerable toxicity as second-line treatment in patients with HER2-positive MBC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence.
- Author
-
Zhou, Danyang, Li, Mei, Xu, Fei, Zheng, Qiufan, Lu, Qianyi, Hong, Ruoxi, and Wang, Shusen
- Subjects
EPIDERMAL growth factor receptors ,BREAST cancer ,CANCER patients - Abstract
To assess the prognostic significance of skin involvement in breast cancer patients with chest wall recurrence (CWR). We retrospectively analyzed the clinicopathological data of breast cancer patients with CWR who were diagnosed pathologically between January 2000 and April 2020. Disease-free survival (DFS) was the time from radical resection for CWR to disease recurrence. Progression-free survival (PFS) was defined as the time from the diagnosis of locally unresectable CWR to the first sign of disease progression. Persistent chest wall progression was defined as three consecutive chest wall progressions with no distant organ involvement. A total of 476 patients with CWR were included in this study. Skin involvement was confirmed in 345 patients. Skin involvement was significantly correlated with a high T stage (p = 0.003), more positive nodes at initial examination (p < 0.001) and lymphovascular invasion (p < 0.001). Kaplan–Meier analysis showed that skin involvement was a predictor of shorter DFS (p < 0.001), including both local disease progression (p < 0.001) and distant disease progression (p = 0.022). Multivariate analysis showed that skin involvement was an independent biomarker for DFS (p = 0.043). Patients with skin involvement were more likely to experience persistent chest wall progression (p = 0.040). After eliminating the potential deviation caused by an insufficient follow-up time, persistent chest wall progression was more likely to be associated with a high N stage (p = 0.002), negative progesterone receptor (PR; p = 0.001) and positive human epidermal growth factor receptor 2 (HER2; p = 0.046) of the primary site, and negative oestrogen receptor (ER; p = 0.027) and PR (p = 0.013) of the chest wall lesion and skin involvement (p = 0.020). Skin involvement was a predictor of poor disease control in patients with CWR and was closely related to persistent chest wall progression. We stratified the prognosis of individualized treatment for breast cancer patients with CWR to provide new insights into the biological behaviours of the disease. Skin involvement is a predictor of poor local disease control in breast cancer patients with CWR and a factor contributing to persistent chest wall progression after CWR. We stratified the prognosis of individualized treatment for breast cancer patients with CWR. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Genetic analysis of oligo-recurrence breast cancer: correlation with clinical outcomes.
- Author
-
Jiang, Kuikui, Zhou, Danyang, Xu, Fei, Xia, Wen, Zheng, Qiufan, Lu, Qianyi, Luo, Rongzhen, Hong, Ruoxi, and Wang, Shusen
- Subjects
BREAST cancer ,METASTATIC breast cancer ,TREATMENT effectiveness ,PROGNOSIS ,CANCER patients ,CANCER relapse ,DISEASE progression - Abstract
Background: We aimed to identify the relationship between the genomic characteristics and clinical outcomes of oligo-metastatic breast cancer. Methods: Oligo-metastatic breast cancer diagnosed by pathology from January 2001 and August 2019 were reviewed and we matched the poly-metastatic patients based on the clinicopathological features of patients included. Clinicopathological values and data of genomic alterations were collected. Oligo-recurrence (oligo-R) was defined as a situation where disease progression occurred in less than 5 anatomical sites and other anatomic areas still suppressed by the ongoing therapy. Results: A total of 26 breast cancer patients were enrolled in our study, including 14 patients with strict oligo-metastatic disease (oligo-R > 6 months) and 12 with simultaneous poly-metastatic disease. PIK3CA, TP53 and ERBB2 were the most common shared alterations identified in patients included. Based on the median time of oligo-R, we divided the patients with oligo-metastasis into longer oligo-R group (oligo-R > 31.04 months) and shorter oligo-R group (oligo-R ≤ 31.04 months). The analysis of PIK3CA mutation sites showed that H1047R mutation was closely associated with oligo-metastasis, rather than poly-metastasis. H1047R mutation also predicted a better prognosis (oligo-R > 31.04 months) in oligo-metastatic breast cancer. In addition, HER2 positive was more likely to be related to a good outcome in patients with oligo-metastasis. Conclusions: Through the genetic analysis of samples from oligo-metastasis, we found the prognostic values of PIK3CA H1047R and HER2 in oligo- and poly-metastasis. We improved the stratification of prognosis and provided new insights for biological behaviors of oligo-metastatic breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. What is the appropriate genetic testing criteria for breast cancer in the Chinese population?—Analysis of genetic and clinical features from a single cancer center database.
- Author
-
Ni, Mengqian, Wang, Fang, Yang, Anli, Shao, Qiong, Xue, Cong, Xia, Wen, Xu, Fei, Lin, Xi, Huang, Jiajia, Bi, Xiwen, Hong, Ruoxi, Chen, Meiting, Zheng, Qiufan, Jiang, Kuikui, Xie, Xinhua, Tang, Jun, Wang, Xi, Yuan, Zhongyu, Wang, Shusen, and Shi, Yanxia
- Subjects
GENETIC testing ,CHINESE people ,BRCA genes ,BREAST cancer ,DATABASES ,HEREDITARY nonpolyposis colorectal cancer - Abstract
Background: Genetic testing plays an important role in guiding screening, diagnosis, and precision treatment of breast cancer (BC). However, the appropriate genetic testing criteria remain controversial. The current study aims to facilitate the development of suitable strategies by analyzing the germline mutational profiles and clinicopathological features of large‐scale Chinese BC patients. Methods: BC patients who had undergone genetic testing at the Sun Yat‐sen University Cancer Center (SYSUCC) from September 2014 to March 2022 were retrospectively reviewed. Different screening criteria were applied and compared in the population cohort. Results: A total of 1035 BC patients were enrolled, 237 pathogenic or likely pathogenic variants (P/LPV) were identified in 235 patients, including 41 out of 203 (19.6%) patients tested only for BRCA1/2 genes, and 194 out of 832 (23.3%) received 21 genes panel testing. Among the 235 P/LPV carriers, 222 (94.5%) met the NCCN high‐risk criteria, and 13 (5.5%) did not. While using Desai's criteria of testing, all females diagnosed with BC by 60 years and NCCN criteria for older patients, 234 (99.6%) met the high‐risk standard, and only one did not. The 21 genes panel testing identified 4.9% of non‐BRCA P/LPVs and a significantly high rate of variants of uncertain significance (VUSs) (33.9%). The most common non‐BRCA P/LPVs were PALB2 (11, 1.3%), TP53 (10, 1.2%), PTEN (3, 0.4%), CHEK2 (3, 0.4%), ATM (3, 0.4%), BARD1 (3, 0.4%), and RAD51C (2, 0.2%). Compared with BRCA1/2 P/LPVs, non‐BRCA P/LPVs showed a significantly low incidence of NCCN criteria listed family history, second primary cancer, and different molecular subtypes. Conclusions: Desai's criteria might be a more appropriate genetic testing strategy for Chinese BC patients. Panel testing could identify more non‐BRCA P/LPVs than BRCA1/2 testing alone. Compared with BRCA1/2 P/LPVs, non‐BRCA P/LPVs exhibited different personal and family histories of cancer and molecular subtype distributions. The optimal genetic testing strategy for BC still needs to be investigated with larger continuous population studies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Current Situation of Diagnosis and Treatment of HER2-Positive Metastatic Breast Cancer Patients in China: A Nationwide Cross-Sectional Survey of Doctors.
- Author
-
Jiang, Kuikui, Zhou, Danyang, Hong, Ruoxi, Lu, Qianyi, Xu, Fei, Xia, Wen, Zheng, Qiufan, and Wang, Shusen
- Subjects
TRASTUZUMAB ,HER2 positive breast cancer ,METASTATIC breast cancer ,PHYSICIANS ,CANCER patients ,EPIDERMAL growth factor receptors - Abstract
Background: The Advanced Breast Cancer Alliance conducted a nationwide investigation to understand the current situation of the diagnosis and treatment of human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) patients. Methods: In 2019, electronic questionnaires including basic information about respondents, characteristics of patients, and the present status of diagnosis and treatment were sent to 495 doctors from 203 medical centers covering 28 provinces. Results: The factors that influenced treatment plans included the disease process, the performance status, and the economic status of patients. Regimens and response to neoadjuvant/adjuvant chemotherapy were important factors in the decision of the first-line treatment. Overall, 54% of doctors retained trastuzumab and replaced chemotherapy drugs in second-line treatment regimens for patients with progression-free survival (PFS) ≥ 6 months in the first-line setting, while 52% of participants chose pyrotinib plus capecitabine for patients with PFS < 6 months. Economic factors played an important role in doctors' decision-making and the varying treatment options for respondents in first-tier, second-tier, and other cities. Conclusions: This large-scale survey regarding the diagnosis and treatment of HER2-positive MBC patients revealed that clinical decisions made by Chinese doctors followed the guidelines, but their choices were constrained by economic factors. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
7. Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study.
- Author
-
Zheng, Qiufan, Luo, Hanjia, Xia, Wen, Lu, Qianyi, Jiang, Kuikui, Hong, Ruoxi, Xu, Fei, and Wang, Shusen
- Abstract
Purpose: Findings from randomized clinical trials have shown that survival in patients with sentinel lymph node (SLN)-negative breast cancer is noninferior with SLN biopsy (SLNB) alone versus further axillary lymph node dissection (ALND). However, the long-term outcome of these two surgical approaches in pN0 breast cancer patients in real-world setting remains uncertain. Methods: We included patients diagnosed with pathologically staged T1-2N0M0 breast cancer between 2000 and 2015 in surveillance, epidemiology, and end results 18-registry database. Patients were considered to have undergone SLNB alone if they had ≤ 5 examined lymph nodes (ELNs), and ALND if they had ≥ 10 ELNs. The outcomes included overall survival (OS) and breast cancer-specific survival. Propensity score analyses by weighting and matching and multivariable Cox regression analysis were performed to minimize treatment selection bias. Results: We included 309,430 patients (253,501 SLNB and 55,929 ALND). In the weighted cohort, ALND was associated with significantly lower OS (hazard ratio [HR] 1.13; 95% confidence interval [CI] 1.10–1.16) and BCSS (HR 1.16; 95% CI 1.10–1.22) compared with SLNB alone. Both the propensity score-matching model and multivariable Cox model demonstrated a survival benefit for SLNB when compared with ALND. Subgroup analyses for key variables did not change these findings. Conclusion: We found statistically significant differences in OS and BCSS between SLNB and ALND, though the magnitude of these differences was small. Our findings further support that SLNB alone should be the standard of care for patients who do not have metastatic lymph nodes identified during breast cancer surgery. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Systemic Therapy Combined with Locoregional Therapy Improved Survival in Oligometastatic Breast Cancer: A Single-Center Retrospective Cohort Study.
- Author
-
Ma, Yuyu, Duan, Fangfang, Zhuang, Yue, Song, Chenge, Huang, Jiajia, Xia, Wen, Hong, Ruoxi, Zheng, Qiufan, Wang, Shusen, Shi, Yanxia, Xu, Fei, Yuan, Zhongyu, and Bi, Xiwen
- Subjects
BREAST tumor treatment ,BREAST cancer prognosis ,THERAPEUTIC use of antineoplastic agents ,RESEARCH ,SCIENTIFIC observation ,METASTASIS ,RETROSPECTIVE studies ,SURVIVAL analysis (Biometry) ,DESCRIPTIVE statistics ,PROGRESSION-free survival ,LONGITUDINAL method - Abstract
The optimal therapeutic options, adding locoregional therapy (LRT) to systemic therapy (ST) or not, for patients with oligometastatic breast cancer (OMBC) have not been fully elucidated. Hence, we designed a retrospective observational study which enrolled patients with measurable extracranial OMBC having less than 5 metastatic lesions not necessarily in the same organ. We retrospectively reviewed a total of 199 patients diagnosed with extracranial OMBC, including 28 receiving ST followed by LRT (ST to LRT group), 44 receiving LRT followed by ST (LRT to ST group), and 127 receiving ST alone (ST alone group). After a median follow-up of 28.7 months, patients receiving both ST and LRT had a significantly better prognosis than those receiving ST alone: the median progression-free survival (PFS) was 16.3, 14.0, and 9.3 months (P < 0.001) and the median overall survival (OS) was 39.8, 70.5, and 26.7 months (P < 0.001) in the ST to LRT, LRT to ST, and ST alone groups, respectively. Sequence of ST and LRT had no significant impact on survival among patients receiving both. Further exploratory analysis identified ST plus LRT as an independent predictor for longer PFS. In conclusion, we demonstrated that adding LRT to ST was associated with survival benefits for patients with OMBC, and further prospective studies were warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
9. Clinical genomic profiling to identify actionable alterations for very early relapsed triple-negative breast cancer patients in the Chinese population.
- Author
-
Wang, Liye, Zhai, Qinglian, Lu, Qianyi, Lee, Kaping, Zheng, Qiufan, Hong, Ruoxi, and Wang, Shusen
- Subjects
TRIPLE-negative breast cancer ,CHINESE people ,CANCER patients ,CANCER relapse ,NUCLEOTIDE sequencing ,GENE rearrangement - Abstract
Triple-negative breast cancer (TNBC) represents about 19% of all breast cancer cases in the Chinese population. Lack of targeted therapy contributes to the poorer outcomes compared with other breast cancer subtypes. Comprehensive genomic profiling helps to explore the clinically relevant genomic alterations (CRGAs) and potential therapeutic targets in very-early-relapsed TNBC patients. Formalin-fixed paraffin-embedded (FFPE) tumour tissue specimens from 23 patients with very-early-relapsed TNBC and 13 patients with disease-free survival (DFS) more than 36 months were tested by FoundationOne CDx (F1CDx) in 324 genes and select gene rearrangements, along with genomic signatures including microsatellite instability (MSI) and tumour mutational burden (TMB). In total, 137 CRGAs were detected in the 23 very-early-relapsed TNBC patients, averaging six alterations per sample. The mean TMB was 4 Muts/Mb, which was higher than that in non-recurrence patients, and is statistically significant. The top-ranked altered genes were TP53 (83%), PTEN (35%), RB1 (30%), PIK3CA (26%) and BRCA1 (22%). RB1 mutation carriers had shorter DFS. Notably, 100% of these patients had at least one CRGA, and 87% of patients had at least one actionable alteration. In pathway analysis, patients who carried a mutation in the cell cycle pathway were more likely to experience very early recurrence. Strikingly, we detected one patient with ERBB2 amplification and one patient with ERBB2 exon20 insertion, both of which were missed by immunohistochemistry (IHC). We also detected novel alterations of ROS1–EPHA7 fusion for the first time, which has not been reported in breast cancer before. The comprehensive genomic profiling can identify novel treatment targets and address the limited options in TNBC patients. Therefore, incorporating F1CDx into TNBC may shed light on novel therapeutic opportunities for these very-early-relapsed TNBC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Distribution Characteristics and Prognostic Value of Immune Infiltration in Oligometastatic Breast Cancer.
- Author
-
Zhou, Danyang, Jiang, Kuikui, Hong, Ruoxi, Lu, Qianyi, Xia, Wen, Li, Mei, Zheng, Chengyou, Zheng, Qiufan, Xu, Fei, and Wang, Shusen
- Subjects
PROGNOSIS ,BREAST cancer ,BIOMARKERS ,KI-67 antigen ,SURVIVAL analysis (Biometry) - Abstract
Background: To assess the distribution characteristics and the prognostic value of immune infiltration in female oligometastatic breast cancer patients. Methods: We retrospectively analyzed the clinicopathological data of oligometastatic breast cancer (OMBC) patients diagnosed between June 2000 and January 2020. Immune markers were quantified by immunohistochemistry on FFPE tissues in paired normal breast tissues, primary breast cancers and oligometastatic lesions. Survival analyses were performed using the Kaplan-Meier curves and Cox-proportional hazards model. Results: A total of 95 female OMBC patients visited Sun Yat-sen University Cancer Center between June 2000 and January 2020, and 33 of them had matched normal breast tissues, primary cancers and oligometastatic lesions and were reviewed in immune infiltration analysis. CD8 of primary tumors had a higher expression than that in matched normal tissues. The expressions of CD8 and FOXP3 were higher in the primary sites than that in the oligometastatic lesions. CD3, CD4 and CD8 were significantly lower in the intratumoral regions than that in the peritumoral regions both in primary and oligometastatic lesions. Notably, the high percentage of CD3 in the intratumoral oligometastatic lesions predicted the longer PFS and OS, and higher CD4 in the same lesions also predicted a better OS. There was obviously positive correlation between CD4/CD3 and Ki-67 in primary cancers and negative correlation between CD4/CD3 and ER in oligometastatic sites. Conclusion: We explored immune distribution and evolution in time and space in OMBC to provide new understandings for biological behaviors of this disease and further divided patients in different prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
11. A Phase II Study of Fulvestrant 500 mg as Maintenance Therapy in Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Patients with Advanced Breast Cancer After First‐Line Chemotherapy.
- Author
-
Xu, Fei, Zheng, Qiufan, Xia, Wen, Ouyang, Quchang, Pang, Danmei, Yuan, Zhongyu, Shi, Yanxia, Peng, Roujun, Lu, Qianyi, and Wang, Shusen
- Subjects
DRUG efficacy ,DISEASE progression ,INJECTIONS ,CLINICAL trials ,CONFIDENCE intervals ,ANTINEOPLASTIC agents ,TREATMENT effectiveness ,DESCRIPTIVE statistics ,POSTMENOPAUSE ,SURVIVAL analysis (Biometry) ,ODDS ratio ,HORMONE receptor positive breast cancer ,PATIENT safety ,EVALUATION - Abstract
Lessons Learned: Fulvestrant 500 mg maintenance therapy showed a clinical benefit rate of 76% and median progression‐free survival of 16.1 months in patients who achieved objective responses or disease control after first‐line chemotherapy.Adverse events with fulvestrant maintenance therapy were consistent with the known safety profile of the drug. Background: Evidence for maintenance hormonal therapy after chemotherapy for estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer is scarce. This study aimed to evaluate the efficacy of fulvestrant 500 mg maintenance therapy in patients after first‐line chemotherapy. Methods: We enrolled postmenopausal women with ER‐positive/HER2‐negative advanced breast cancer who attained tumor responses or disease control with four to eight cycles of chemotherapy as first‐line treatment. Fulvestrant 500 mg was injected on days 1, 15, and 29 and every 28 (±3) days thereafter. The primary endpoint was the clinical benefit rate (CBR); the secondary endpoints included the objective response rate (ORR), progression‐free survival (PFS), and safety. Results: We included 58 patients; the median follow‐up duration was 32.6 months. The CBR since commencing fulvestrant maintenance therapy was 76% (95% confidence interval [CI], 63%–86%), and ORR was 14% (95% CI, 6%–25%); eight patients achieved partial response. The median PFS for fulvestrant maintenance therapy was 16.1 months (95% CI, 10.3–21.0 months). Thirty‐nine patients (67%) reported at least one adverse event, of which most were grade 1/2, whereas three patients (5%) reported grade 3 adverse events. Conclusion: Fulvestrant 500 mg is a feasible and promising hormonal maintenance strategy in patients with ER‐positive/HER2‐negative advanced breast cancer who have no disease progression after first‐line chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
12. EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non‐small cell lung cancer patients.
- Author
-
Zheng, Qiufan, Hong, Shaodong, Huang, Yan, Zhao, Hongyun, Yang, Yunpeng, Hou, Xue, Zhao, Yuanyuan, Ma, Yuxiang, Zhou, Ting, Zhang, Yaxiong, Fang, Wenfeng, and Zhang, Li
- Subjects
NON-small-cell lung carcinoma ,METADATA ,TREATMENT effectiveness ,EPIDERMAL growth factor receptors ,CIRCULATING tumor DNA ,CANCER patients ,OSIMERTINIB - Abstract
publisher‐imprint‐name Springer volume‐issue‐count 1 issue‐article‐count 17 issue‐toc‐levels 0 issue‐pricelist‐year 2020 issue‐copyright‐holder The Author(s) issue‐copyright‐year 2020 article‐contains‐esm Yes article‐numbering‐style Unnumbered article‐registration‐date‐year 2020 article‐registration‐date‐month 2 article‐registration‐date‐day 4 article‐toc‐levels 0 toc‐levels 0 volume‐type Regular journal‐product ArchiveJournal numbering‐style Unnumbered article‐grants‐type OpenChoice metadata‐grant OpenAccess abstract‐grant OpenAccess bodypdf‐grant OpenAccess bodyhtml‐grant OpenAccess bibliography‐grant OpenAccess esm‐grant OpenAccess online‐first false pdf‐file‐reference BodyRef/PDF/40169_2020_Article_269.pdf pdf‐type Typeset target‐type OnlinePDF issue‐type Regular article‐type OriginalPaper journal‐subject‐primary Medicine & Public Health journal‐subject‐secondary Medicine/Public Health, general journal‐subject‐collection Medicine open‐access true --> Background: Despite the impressive anti‐tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M‐positive non‐small cell lung cancer (NSCLC) patients, 30–40% of patients still show limited response. There is therefore a need to identify biomarkers that accurately predict the response to osimertinib therapy. In this study, 54 patients with targeted next‐generation sequencing of circulating tumor DNA before osimertinib treatment and known T790M positivity were included. We investigated the predictive value of baseline circulating tumor DNA‐derived biomarkers on osimertinib therapy. Results: Baseline maximum somatic allele frequency (MSAF) level was not associated with objective response rate (ORR) (P = 0.886) and progression‐free survival (PFS) (P = 0.370) of osimertinib treatment. T790M relative mutation purity (RMP, defined here as the ratio of T790M AF to MSAF) quartiles were found to be significantly associated with ORR (P for trend = 0.002) and PFS (P for trend = 0.006), and a cut off value of 0.24 identified two distinct prognostic groups [Hazard ratio (HR) = 0.36 for low T790M RMP, 95% confidence interval (CI) 0.18–0.72, P = 0.004). Additionally, although T790M relative mutation abundance (RMA, defined as T790M AF/EGFR driver AF) quartiles were not significantly associated with ORR (P for trend = 0.063), a cut off value of 0.30 also identified two distinct prognostic groups (HR = 0.43 for low T790M RMA, 95% CI 0.22–0.85, P = 0.015). However, in multivariate analysis, grouping of T790M RMP showed a better predictive value (HR = 0.46, 95% CI 0.20–1.05, P = 0.066) than T790M RMA (HR = 0.71, 95% CI 0.31–1.61, P = 0.409). Moreover, T790M RMP as continuous covariate was independently predictive of PFS (HR = 0.15, 95% CI 0.03–0.79, P =0.025), while T790M RMA was not (HR = 1.14, 95% CI 0.49–2.66, P =0.766). An external validation cohort further confirmed the T790M RMP was significantly associated with PFS of osimertinib therapy. Conclusions: This study established the independent predictive role of T790M RMP in NSCLC patients receiving osimertinib treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Administration of Lapatinib with Food Increases Its Plasma Concentration in Chinese Patients with Metastatic Breast Cancer: A Prospective Phase II Study.
- Author
-
Xu, Fei, Lee, Kaping, Xia, Wen, Liao, Hai, Lu, Qianyi, Zhang, Jingmin, Yuan, Huimin, Zhang, Kai, Zheng, Qiufan, Qin, Ge, Zhai, Qinglian, Hong, Ruoxi, Jiang, Kuikui, Li, Yuan, and Wang, Shusen
- Subjects
ACADEMIC medical centers ,ANTINEOPLASTIC agents ,BLOOD plasma ,BREAST tumors ,CANCER patients ,CLINICAL trials ,INGESTION ,LIQUID chromatography ,METASTASIS ,PROTEIN-tyrosine kinase inhibitors ,DESCRIPTIVE statistics ,PHARMACODYNAMICS - Abstract
Lessons Learned: Administration of lapatinib with food significantly increased its plasma concentration in Chinese patients with metastatic breast cancer.There were no serious adverse events during the study and no significant differences in lapatinib‐related adverse events between the fasted and fed states. Background: Lapatinib, a small molecular reversible dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth receptor 2 (HER2), was approved for use in combination with capecitabine to treat metastatic HER2‐positive breast cancer. Administration of lapatinib in the fasted state was recommended; however, our preliminary phase II trial data showed that administration of lapatinib with food increased its concentration. Methods: This study was a single‐center, open‐label, and prospective self‐controlled clinical study. Ten Chinese patients with metastatic breast cancer were enrolled from June 2017 to April 2018. They were required to receive lapatinib plus physician's choice of chemotherapy. Patients were required to take lapatinib orally on an empty stomach continually for 10 days, and then take lapatinib with food continually for the next 10 days. Plasma concentration was measured by liquid chromatography on the 9th and 10th day of each state. Results: Area under the concentration‐time curve (AUC) of the fasted state and the fed state was 21.23 ± 8.91 mg*h/L (coefficient of variation (CV)% 42%) and 60.60 ± 16.64 mg*h/L (CV% 27%), respectively. The mean plasma concentration in the fasted state was 0.88 ± 0.39 mg/L (CV% 45%), and that in the fed state was 2.53 ± 0.77 mg/L (CV% 30%). Compared with taking lapatinib on an empty stomach, receiving lapatinib with food significantly increased the plasma concentration of lapatinib (Wilcoxon match‐paired test, p =.005). In addition, there were no serious adverse events during the study or significant difference in lapatinib‐related adverse events between the two states. Conclusion: Our study shows that receiving lapatinib with food can increase its plasma concentration with no significantly increased drug‐related toxicity. We suggest that a larger‐sample‐size clinical trial is needed to fully understand the effect of administration of lapatinib with food. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center.
- Author
-
Lu, Qianyi, Lee, Kaping, Xu, Fei, Xia, Wen, Zheng, Qiufan, Hong, Ruoxi, Jiang, Kuikui, Zhai, Qinglian, Li, Yuan, Shi, Yanxia, Yuan, Zhongyu, and Wang, Shusen
- Published
- 2020
- Full Text
- View/download PDF
15. EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non‐small cell lung cancer patients.
- Author
-
Zheng, Qiufan, Hong, Shaodong, Huang, Yan, Zhao, Hongyun, Yang, Yunpeng, Hou, Xue, Zhao, Yuanyuan, Ma, Yuxiang, Zhou, Ting, Zhang, Yaxiong, Fang, Wenfeng, and Zhang, Li
- Subjects
NON-small-cell lung carcinoma ,METADATA ,TREATMENT effectiveness ,EPIDERMAL growth factor receptors ,CIRCULATING tumor DNA ,CANCER patients - Abstract
publisher‐imprint‐name Springer volume‐issue‐count 1 issue‐article‐count 17 issue‐toc‐levels 0 issue‐pricelist‐year 2020 issue‐copyright‐holder The Author(s) issue‐copyright‐year 2020 article‐contains‐esm Yes article‐numbering‐style Unnumbered article‐registration‐date‐year 2020 article‐registration‐date‐month 2 article‐registration‐date‐day 4 article‐toc‐levels 0 toc‐levels 0 volume‐type Regular journal‐product ArchiveJournal numbering‐style Unnumbered article‐grants‐type OpenChoice metadata‐grant OpenAccess abstract‐grant OpenAccess bodypdf‐grant OpenAccess bodyhtml‐grant OpenAccess bibliography‐grant OpenAccess esm‐grant OpenAccess online‐first false pdf‐file‐reference BodyRef/PDF/40169_2020_Article_269.pdf pdf‐type Typeset target‐type OnlinePDF issue‐type Regular article‐type OriginalPaper journal‐subject‐primary Medicine & Public Health journal‐subject‐secondary Medicine/Public Health, general journal‐subject‐collection Medicine open‐access true --> Background: Despite the impressive anti‐tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M‐positive non‐small cell lung cancer (NSCLC) patients, 30–40% of patients still show limited response. There is therefore a need to identify biomarkers that accurately predict the response to osimertinib therapy. In this study, 54 patients with targeted next‐generation sequencing of circulating tumor DNA before osimertinib treatment and known T790M positivity were included. We investigated the predictive value of baseline circulating tumor DNA‐derived biomarkers on osimertinib therapy. Results: Baseline maximum somatic allele frequency (MSAF) level was not associated with objective response rate (ORR) (P = 0.886) and progression‐free survival (PFS) (P = 0.370) of osimertinib treatment. T790M relative mutation purity (RMP, defined here as the ratio of T790M AF to MSAF) quartiles were found to be significantly associated with ORR (P for trend = 0.002) and PFS (P for trend = 0.006), and a cut off value of 0.24 identified two distinct prognostic groups [Hazard ratio (HR) = 0.36 for low T790M RMP, 95% confidence interval (CI) 0.18–0.72, P = 0.004). Additionally, although T790M relative mutation abundance (RMA, defined as T790M AF/EGFR driver AF) quartiles were not significantly associated with ORR (P for trend = 0.063), a cut off value of 0.30 also identified two distinct prognostic groups (HR = 0.43 for low T790M RMA, 95% CI 0.22–0.85, P = 0.015). However, in multivariate analysis, grouping of T790M RMP showed a better predictive value (HR = 0.46, 95% CI 0.20–1.05, P = 0.066) than T790M RMA (HR = 0.71, 95% CI 0.31–1.61, P = 0.409). Moreover, T790M RMP as continuous covariate was independently predictive of PFS (HR = 0.15, 95% CI 0.03–0.79, P =0.025), while T790M RMA was not (HR = 1.14, 95% CI 0.49–2.66, P =0.766). An external validation cohort further confirmed the T790M RMP was significantly associated with PFS of osimertinib therapy. Conclusions: This study established the independent predictive role of T790M RMP in NSCLC patients receiving osimertinib treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
16. CPSF4 promotes triple negative breast cancer metastasis by upregulating MDM4.
- Author
-
Lee, Kaping, Zheng, Qiufan, Lu, Qianyi, Xu, Fei, Qin, Ge, Zhai, Qinglian, Hong, Ruoxi, Chen, Miao, Deng, Wuguo, and Wang, Shusen
- Published
- 2021
- Full Text
- View/download PDF
17. Intratumor heterogeneity comparison among different subtypes of non-small-cell lung cancer through multi-region tissue and matched ctDNA sequencing.
- Author
-
Zhang, Yaxiong, Chang, Lianpeng, Yang, Yunpeng, Fang, Wenfeng, Guan, Yanfang, Wu, Aiwei, Hong, Shaodong, Zhou, Huaqiang, Chen, Gang, Chen, Xi, Zhao, Shen, Zheng, Qiufan, Pan, Hui, Zhang, Lanjun, Long, Hao, Yang, Haoxian, Wang, Xin, Wen, Zhesheng, Wang, Junye, and Yang, Hong
- Subjects
NON-small-cell lung carcinoma ,NUCLEOTIDE sequencing ,GENETIC mutation ,NEOPLASTIC cell transformation ,TUMORS - Abstract
Understanding of intratumor heterogeneity (ITH) among different non-small cell lung cancer (NSCLC) subtypes is necessary. Whether circulating tumor DNA (ctDNA) profile could represent these ITH is still an open question. We performed 181 multi-region tumor tissues sequencing and matched ctDNA sequencing from 32 operative NSCLC to compare ITH among different NSCLC subtypes, including EGFR-mutant lung adenocarcinoma (LUAD), KRAS-mutant LUAD, EGFR&KRAS-wild-type LUAD, and lung squamous cell carcinoma (LUSC), and examine potential value of ctDNA for ITH analysis. ITH is evaluated by ITH index (ITHi). If the somatic genetic alteration is shared by all the tissue regions, it is defined as trunk mutation. Otherwise, it is called branch mutation. The ITHi will be higher, if the tumor has less trunk mutations. We found EGFR-mutant LUAD showed significantly higher ITHi than KRAS-mutant LUAD/wild-type LUAD (P = 0.03) and numerically higher ITH than LUSC. For trunk mutations, driver mutations were identified at a higher proportion than passenger mutations (60% vs. 40%, P = 0.0023) in overall, especially in EGFR-mutant LUAD (86% vs. 14%, P = 0.0004), while it was opposite in KRAS-mutant LUAD (40% vs. 60%, P = 0.18). For branch mutations, the proportions of driver mutations and passenger mutations were similar for each NSCLC subtype. ctDNA analysis showed unsatisfactory detections of tumor-derived trunk and branch mutations (43% vs. 23%, P = 4.53e-6) among all NSCLC subtypes. In summary, EGFR-mutant LUAD has the highest ITH than other NSCLC subtypes, offering further understanding of tumorigenesis mechanisms among different NSCLC subtypes. Besides, ctDNA maybe not an appropriate method to reflect ITH. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
18. Clinical value of circulating <em>ESR1</em> mutations for patients with metastatic breast cancer: a meta-analysis.
- Author
-
Zhang, Kai, Hong, Ruoxi, Xu, Fei, Xia, Wen, Kaping, Lee, Qin, Ge, Zheng, Qiufan, Lu, Qianyi, Shi, Yan Xia, Yuan, Zhong yu, and Wang, Shusen
- Subjects
ESTROGEN receptors ,METASTATIC breast cancer ,GENETICS of breast cancer ,BREAST cancer treatment ,META-analysis - Abstract
Background: The clinical implication of plasma ESR1 mutations in the estrogen receptor (ER)-positive metastatic breast cancer (MBC) patients who had progressed after prior aromatase inhibitor (AI)-based therapy remains controversial. We conducted the first meta-analysis to investigate the prognostic significance and predictive role of plasma ESR1 mutations in MBC patients with prior exposure to AI therapy. Materials and methods: We searched PubMed, Embase, and Cochrane Library databases for eligible studies. Meta-analysis was conducted to calculate combined hazard ratios (HRs) with 95% CIs for progression-free survival (PFS) and overall survival (OS). Subgroup and sensitivity analyses were also performed. Results: This study enrolled a total of 1,530 patients with ER-positive MBC cases from six articles, including 429 ESR1 mutation carriers (28.04%). Meta-analysis demonstrated that plasma ESR1 mutation carriers had significantly worse PFS (HR: 1.40, 95% CI: 1.17–1.66; P [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
19. Prognostic value of endocrine treatment-related symptoms in patients with breast cancer: a meta-analysis.
- Author
-
Zheng, Qiufan, Xia, Wen, Lu, Qianyi, Hong, Ruoxi, Qin, Ge, Xu, Fei, Qin, Tao, Shi, Yanxia, Yuan, Zhongyu, and Wang, Shusen
- Abstract
Purpose: Endocrine therapy is associated with improved disease-free survival (DFS) in hormone receptor-positive breast cancer, but it is also associated with many adverse events. The aim of this study was to clarify the association between endocrine treatment-related symptoms and treatment efficacy in patients receiving adjuvant endocrine therapy. Method: EMBASE, Web of Science, PubMed, and CENTRAL databases were searched for studies that compared treatment efficacy between patients in whom adverse events did and did not occur during hormone therapy. Hazard ratios (HRs) and associated 95 % confidence intervals (CIs) for DFS and overall survival were estimated and pooled using random-effects models. Results: Of 4665 citations identified, ten studies incorporating 32,192 patients were included in the meta-analysis. The presence of endocrine treatment-related symptoms was associated with improved DFS (HR 0.76; 95 % CI 0.68-0.85). Similar results were observed in patients with vasomotor symptoms (HR 0.76; 95 % CI 0.66-0.87) or musculoskeletal symptoms (HR 0.75; 95 % CI 0.60-0.94), in patients taking an aromatase inhibitor (HR 0.69; 95 % CI 0.57-0.85) or tamoxifen (HR 0.74; 95 % CI 0.60-0.93), and in patients with symptoms at 3-month (HR 0.74; 95 % CI 0.66-0.83), 6-month (HR 0.80; 95 % CI 0.66-0.96), or 12-month follow-up visits (HR 0.75; 95 % CI 0.68-0.83). However, no significant difference in overall survival was observed between patients with or without endocrine treatment-related symptoms (HR 0.82; 95 % CI 0.60-1.11). Sensitivity analysis excluding studies with heterogeneous factors yielded consistent results. No evidence of publication bias was observed. Conclusion: In our meta-analysis, endocrine treatment-related symptoms were shown to correlate with superior DFS and may therefore be useful in predicting treatment efficacy in patients with breast cancer receiving hormone therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
20. Selective Estrogen Receptor Modulator-Associated Nonalcoholic Fatty Liver Disease Improved Survival in Patients With Breast Cancer: A Retrospective Cohort Analysis.
- Author
-
Qiufan Zheng, Fei Xu, Man Nie, Wen Xia, Tao Qin, Ge Qin, Xin An, Cong Xue, Roujun Peng, Zhongyu Yuan, Yanxia Shi, Shusen Wang, Zheng, Qiufan, Xu, Fei, Nie, Man, Xia, Wen, Qin, Tao, Qin, Ge, An, Xin, and Xue, Cong
- Published
- 2015
- Full Text
- View/download PDF
21. Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.
- Author
-
Zheng, Qiufan, Fang, Wenfeng, Huang, Yihua, Gan, Jiadi, and Zhang, Li
- Published
- 2020
- Full Text
- View/download PDF
22. Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy.
- Author
-
Fang, Wenfeng, Huang, Yihua, Gan, Jiadi, Zheng, Qiufan, and Zhang, Li
- Published
- 2020
- Full Text
- View/download PDF
23. Cover Image: Metronomic chemotherapy of cyclophosphamide plus methotrexate for advanced breast cancer: Real‐world data analyses and experience of one center.
- Author
-
Lu, Qianyi, Lee, Kaping, Xu, Fei, Xia, Wen, Zheng, Qiufan, Hong, Ruoxi, Jiang, Kuikui, Zhai, Qinglian, Li, Yuan, Shi, Yanxia, Yuan, Zhongyu, and Wang, Shusen
- Published
- 2020
- Full Text
- View/download PDF
24. The genomic landscape of Epstein-Barr virus-associated pulmonary lymphoepithelioma-like carcinoma.
- Author
-
Hong, Shaodong, Liu, Dongbing, Luo, Shuzhen, Fang, Wenfeng, Zhan, Jianhua, Fu, Sha, Zhang, Yaxiong, Wu, Xuan, Zhou, Huaqiang, Chen, Xi, Chen, Gang, Zhang, Zhonghan, Zheng, Qiufan, Li, Xiaobo, Chen, Jinghao, Liu, Xingmin, Lei, Mengyue, Ye, Chen, Wang, Jian, and Yang, Huanming
- Abstract
Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and distinct subtype of primary lung cancer characterized by Epstein-Barr virus (EBV) infection. Herein, we reported the mutational landscape of pulmonary LELC using whole-exome sequencing, targeted deep sequencing and single-nucleotide polymorphism arrays. We identify a low degree of somatic mutation but widespread existence of copy number variations. We reveal predominant signature 2 mutations and frequent loss of type I interferon genes that are involved in the host-virus counteraction. Integrated analysis shows enrichment of genetic lesions affecting several critical pathways, including NF-κB, JAK/STAT, and cell cycle. Notably, multi-dimensional comparison unveils that pulmonary LELC resemble NPC but are clearly different from other lung cancers, natural killer/T-cell lymphoma or EBV-related gastric cancer in terms of genetic features. In all, our study illustrates a distinct genomic landscape of pulmonary LELC and provides a road map to facilitate genome-guided personalized treatment. The rare lung cancer subtype pulmonary lymphoepithelioma-like carcinoma is linked to Epstein-Barr virus infection. Here, the authors provide a mutational landscape for this cancer, showing a low burden of somatic mutations and high prevalence of copy number variations. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. The correlations of tumor mutational burden among single-region tissue, multi-region tissues and blood in non-small cell lung cancer.
- Author
-
Zhang, Yaxiong, Chang, Lianpeng, Yang, Yunpeng, Fang, Wenfeng, Guan, Yanfang, Wu, Aiwei, Hong, Shaodong, Zhou, Huaqiang, Chen, Gang, Chen, Xi, Zhao, Shen, Zheng, Qiufan, Pan, Hui, Zhang, Lanjun, Long, Hao, Yang, Haoxian, Wang, Xin, Wen, Zhesheng, Wang, Junye, and Yang, Hong
- Subjects
NON-small-cell lung carcinoma ,BLOOD cells - Abstract
High-level tissue tumor mutational burden (tTMB) or blood TMB (bTMB) are associated with better response of immunotherapy in non-small cell lung cancer (NSCLC) patients. However, the correlations of single-region tTMB, multi-region tTMB and bTMB remain to be determined. Moreover, whether intratumor heterogeneity (ITH) has impact on TMB should be clarified. We collected multi-region tumor tissues with matched blood from 32 operative NSCLC and evaluated single-region tTMB, multi-region tTMB and bTMB through a 1021-gene panel sequencing. TMB of > 9 mutations/Mb was classified as high. Besides, we used tTMB fold-change to evaluate the influence of the enrolled region number on tTMB. We found both of single-region tTMB and bTMB showed strong correlations with multi-region tTMB, while the former correlated better (Pearson r = 0.94, P = 2E-84; Pearson r = 0.47, P = 0.0067). It showed extremely high specificity (100%) but low sensitivity (43%) when using bTMB to define TMB-high patients, while most false-negative predictions were in early-stage patients. Compared to single region, we found significantly enhanced tTMB fold-change if taking multi-regions for consideration. However, it showed insignificant tTMB fold-change increase if the included regions' number more than three. Moreover, ITH-high patients had significantly higher tTMB fold-change compared with ITH-low patients (2.32 vs. 1.02, P = 8.879e-05). The conversion rate of tTMB level (tTMB-low to tTMB-high) was numerically higher in ITH-high group than that in ITH-low group (16.67% vs. 3.84%). In summary, single-region tTMB has stronger correlation with multi-region tTMB compared with bTMB. ITH has an impact on tTMB, especially in high-level ITH patients. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
26. The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer.
- Author
-
An, Xin, Xu, Fei, Luo, Rongzhen, Zheng, Qiufan, Lu, Jiabin, Yang, Yanhua, Qin, Tao, Yuan, Zhongyu, Shi, Yanxia, Jiang, Wenqi, and Wang, Shusen
- Subjects
BREAST tumor treatment ,BREAST tumor risk factors ,ENZYME metabolism ,BREAST tumors ,GENE expression ,PROGNOSIS ,TUMOR markers ,TUMOR classification ,DISEASE relapse ,KAPLAN-Meier estimator ,TUMOR grading - Abstract
Background: Topoisomerase II alpha (TOP2A) protein has been shown to be a proliferation marker associated with tumor grade and Ki67 index. The prognostic effect of TOP2A seems different among different subtypes of breast cancer. The current study evaluated the prognostic impact of TOP2A protein on luminal breast cancer.Method: Altogether 434 stage I-II luminal breast cancer patients who underwent curative surgery in Sun Yat-Sen University Cancer Center between 2007 and 2009 were enrolled. TOP2A protein expression was assessed by immunohistochemistry. Clinical and pathological data were retrospectively collected.Result: With a cut-off value of 30%, 127 (29.3%) patients were classified as TOP2A overexpression. TOP2A overexpression was associated with a higher tumor grade and Ki67 index. Patients with TOP2A high expression showed a significantly higher rate of distant metastasis and shorter distant metastasis free survival (DMFS) compared with patients with low TOP2A expression. The prognostic influence of TOP2A expression was more significant in years 5-8 after diagnosis, and more pronounced in stage II patients, luminal B disease, and patients treated with adjuvant endocrine therapy alone. Multivariate survival analysis revealed TOP2A overexpression was an independent fact for worse DMFS.Conclusion: TOP2A protein showed a time dependent influence on prognosis in stage I-II luminal breast cancer, suggesting it might be a potential predictor of late recurrence for this group of patients. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.